Sponsored by François-Xavier Bagnoud Center, School of
Nursing, University of Medicine and Dentistry of New Jersey
and UMDNJ-Center for Continuing and Outreach Education.
This activity is supported by an educational grant from the New Jersey Department of Health and Senior Services (NJDHSS)—Division of HIV, STD and TB Services, through an MOA titled “Education and Training for Physicians and other Healthcare Professionals in the Diagnosis and Treatment of HIV/AIDS.”
Statement of Need
This article reviews New Jersey state legislation on HIV testing in pregnancy and implementation of the law. The second section of the article provides an update on the U.S. Department of Health and Human Services Guidelines for women living with HIV who are pregnant or who are considering pregnancy.
This article aims to respond to questions and confusions amongst healthcare professionals regarding the requirements of the New Jersey legislation on HIV testing in pregnancy, with an emphasis on testing during labor and infant testing. The implementation of New Jersey’s 2007 legislation (NJ P.L. 2007.c.218) regarding HIV testing in pregnancy has had an impact on both health professionals caring for pregnant women and women in care. Under the 2007 legislation HIV testing is included in routine prenatal testing using an “opt-out” approach. That is, the HIV test is conducted routinely, along with the standard battery of prenatal blood tests, unless the woman declines.
Medical management of pregnant women and pregnant women with HIV infection is rapidly evolving. The Perinatal Guidelines are updated at least annually and were most recently released on September 14, 2011. This article provides the reader with a summary of the key changes in the 2011 Perinatal Guidelines. As they are evidence based, the 2011 Perinatal Guidelines update includes an extensive review of the existing and newly reported clinical trial results that informed the authoring Panel’s recommendations. This article provides an overview of some of the key trials cited in the 2011 update, to support physician use of evidence based medicine.
This activity is designed for physicians, nurses, social workers, and other health care professionals in New Jersey who are involved in the care of women with HIV.
Method of Participation
Participants should read the learning objectives, review the activity in its entirety, and then complete the self-assessment test, which consists of a series of multiple-choice questions. Upon completing this activity as designed, achieving a passing score of 70% or more on the self-assessment test and submitting a course evaluation, participants will have access to an online printable credit statement.
Estimated time to complete this activity as designed is 1.35 hours for nurses, and 2.0 hours for physicians.
Upon completion of this activity, participants should be able to:
- Recognize the implications of New Jersey’s 2007 legislation on HIV testing in pregnancy to reduce perinatal HIV transmission.
- Identify the 2011 updates to the Perinatal Guidelines that will have an impact on current practice.
- Describe research findings that influence the 2011 Perinatal Guidelines update.
Activity Director(s)/CME Academic Advisor(s)
Patricia Kloser, MD, MPH,
Professor of Medicine, UMDNJ-New Jersey Medical School and UMDNJ-School of Public Health
Sindy Paul, MD, MPH, FACPM, Medical Director, Division of HIV, STD and TB Services, New Jersey Department of Health and Senior Services
Kimi Nakata, MSW, MPH, UMDNJ-CCOE-Division of AIDS Education Program Supervisor and Editor, NJ AIDSLine (until February 2012)
Virginia Allread, MPH, Editor NJ AIDSLine (February 2012 to present) and Director of Global Programs, FXB Center, School of Nursing, UMDNJ
Joanne Phillips, MSN, PNP, BSN, Education Specialist, FXB Center, School of Nursing, UMDNJ
Renee Powell, MS, RN, Clinical Coordinator, Quality Management, FXB Center, School of Nursing, UMDNJ
Elizabeth Ward, MSJ, Director, CME Compliance and Administration, UMDNJ-CCOE
Brenda Christian, Med, PA-C, UMDNJ-CCOE, Director, Division of AIDS Education (until February 2012)
Carolyn Burr, EdD, RN, Deputy Executive Director, FXB Center,
School of Nursing, UMDNJ
Zeina Ghayad, DO, Infectious Disease Fellow, PGY – 5, UMDNJ-SOM/Kennedy Memorial Hospital
Sindy Paul, MD,MPH, FACPM, Medical Director, Division of HIV, STD and TB Services
Credit is no longer available for this activity.
In order to help ensure content objectivity, independence, and fair balance, and to ensure that the content is aligned with the interest of the public, UMDNJ-CCOE has resolved all potential and real conflicts of interest through content review by non-conflicted, qualified reviewers. This activity was peer-reviewed for relevance, accuracy of content and balance of presentation by Shin-Pung Polly Jen, PharmD, BCPS; John J. Faragon, PharmD; Joanne Phillips, RN, MS; and Renee Powell, MS, RN.
This activity was pilot-tested for time required for participation by Bonnie R. Abedini, MSN, RN; Jojy Cheriyan, MD, MPH, MPhil; Anna M. Haywood, RN, MSN; Patricia Kloser, MD, MPH; Mary C. Krug, RN, MSN, APN; and Kara Winslow, BSN, RN.
In accordance with the disclosure policies of UMDNJ and to conform with ACCME and FDA guidelines, individuals in a position to control the content of this educational activity are required to disclose to the activity participants: 1) the existence of any relevant financial relationship with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients, with the exemption of non-profit or government organizations and non-health care related companies, within the past 12 months; and 2) the identification of a commercial product/device that is unlabeled for use or an investigational use of a product/ device not yet approved.
There were no relevant financial relationships to disclose reported by the activity director, authors, planning committee members, peer reviewers or field testers.
Off-Label Usage Disclosure
This activity does not contain information of commercial products/devices that are unlabeled for use or investigational uses of products not yet approved.
The views expressed in this activity are those of the faculty. It should not be inferred or assumed that they are expressing the views of NJDHSS – Division of HIV, STD and TB Services, any manufacturer of pharmaceuticals or devices, or UMDNJ. It should be noted that the recommendations made herein with regard to the use of therapeutic agents, varying disease states, and assessments of risk, are based upon a combination of clinical trials, current guidelines, and the clinical practice experience of the participating presenters. The drug selection and dosage information presented in this activity are believed to be accurate. However, participants are urged to consult all available data on products and procedures before using them in clinical practice.
Copyright © 2012 UMDNJ
All rights reserved including translation into other languages. No part of this activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval systems, without permission in writing from UMDNJ.
Please direct CE related or technical questions to UMDNJ at 973-972-4267 or email email@example.com.